Article Text

Download PDFPDF

Response to: ‘Autoinflammatory disease damage index (ADDI): a possible newborn also in hidradenitis suppurativa daily practice’ by Damiani et al
  1. Kim V Annink1,
  2. Nienke M ter Haar2,3,
  3. Joost Frenkel1
  1. 1 Department of Paediatrics, University Medical Centre Utrecht, Utrecht, The Netherlands
  2. 2 Laboratory for Translational Immunology, University Medical Centre Utrecht, Utrecht, The Netherlands
  3. 3 Department of Paediatric Immunology, University Medical Centre Utrecht, Utrecht, The Netherlands
  1. Correspondence to Professor Joost Frenkel, Wilhelmina Children's Hospital, Room KE 04 133 1, Lundlaan 6, PO Box 85090, Utrecht 3508 AB, The Netherlands; j.frenkel{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

We thank Dr Damiani et al 1 for their interesting letter about the utility of the autoinflammatory disease damage index (ADDI) in patients with hidradenitis suppurativa (HS), as a response to our recently published article ‘The development of the autoinflammatory disease damage index’.2 It is important to investigate whether the ADDI is also useful for other autoinflammatory diseases. However, we need to consider that the ADDI is developed and will be validated for familial Mediterranean fever, cryopyrin-associated periodic syndromes, tumour necrosis factor receptor-associated periodic fever syndrome and mevalonate kinase deficiency only. The selection of items was based on an intensive literature search and consensus procedure, to make sure all (and only) relevant items for these four diseases were covered.2 HS-specific damage, such as disfiguring scars, will not be measured by the ADDI, although this damage might have an important influence on the patients' daily life.3 As mentioned in the letter, prospective validation of the ADDI in patients with HS is essential before it can be used in the daily practice. We are looking forward to these results.



  • Contributors The authors wrote the response to the eLetter.

  • Competing interests None declared.

  • Provenance and peer review Commissioned; internally peer reviewed.

Linked Articles